Condition: Sarcoma,Soft Tissue · Pulmonary Metastasis · Sponsor: Moleculin Biotech, Inc.
This is a multi-center, open-label, single-arm study that in Phase 1b will determine the maximum tolerated dose (MTD)/ recommended phase 2 dose (RP2D) and safety of L-Annamycin and in Phase 2 will explore the efficacy of L- Annamycin as a single agent for the treatment of subjects with STS with lung metastases for which chemotherapy is considered appropriate.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Sarcoma Oncology Center | Santa Monica, California, United States | — |
| Washington University | St Louis, Missouri, United States | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick, New Jersey, United States | — |
| Ohio State University | Columbus, Ohio, United States | — |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04887298